Metastatic Small Cell Lung Cancer Post Platinum Therapy Therapeutics
1. Zepzelca patent expiration
Treatment: Treating metastatic sclc after platinum chemotherapy with lurbinectedin monotherapy by reducing the dose for grade ≥3 hepatotoxicity from 3.2 to 2.6 mg/m2 and 2.6 to 2.0 mg/m2 lurbinectedin within 35 ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7763615 | JAZZ | Ecteinascidin analogs for use as antitumour agents |
Dec, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12324806 | JAZZ | Method of treating SCLC and managing hepatotoxicity |
May, 2040
(14 years from now) | |
| US12433890 | JAZZ | NA |
May, 2040
(14 years from now) | |
| US12440490 | JAZZ | NA |
May, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 15, 2025 |
| Orphan Drug Exclusivity(ODE-304) | Jun 15, 2027 |
Drugs and Companies using LURBINECTEDIN ingredient
NCE-1 date: 15 June, 2024
Market Authorisation Date: 15 June, 2020
Dosage: POWDER
More Information on Dosage
ZEPZELCA family patents
